• FDA OKs a new COVID-19 prevention drug

    On March 22, the FDA granted emergency use authorization to Pemgarda, a COVID-19 preventive medication, for patients 12 and older. 
  • Transform Your Hospital Operations: A Virtual Summit

    Sponsored
    Nearly 190 health systems are reimagining hospital operations with AI. Learn how, here.
  • FDA approves 1st nonsteroidal drug for Duchenne muscular dystrophy

    The FDA has approved Duvyzat as the first nonsteroidal drug for patients with all genetic variants of Duchenne muscular dystrophy, the agency said March 21.
  • WVU pharmacists test AI to lessen readmissions, save costs

    Researchers and pharmacists at West Virginia University are developing AI technology to streamline medication reconciliation in hospitals, or the standard of reviewing a patient's drug regimen before discharges. 
  • Albertsons joins Mark Cuban's pharmacy network

    Mark Cuban Cost Plus Drug Co. expanded its pharmacy network March 20 with a deal with grocery chain Albertsons, growing its drug discount offering by another thousand-plus locations. 
  • New gene therapy to cost $4.25M — the highest drug price in US

    The most expensive drug in the U.S. is now Lenmeldy, a $4.25 million gene therapy the FDA approved March 18 for children with a rare genetic disease. 
  • 54% of meds at 'high risk,' military says

    More than half of pharmaceuticals in the United States have a dependency on manufacturers not compliant to the Trade Agreements Act, which the Department of Defense defines as high- and very high-risk medications. 
  • Medication abortions now account for 6 in 10 US abortions

    In 2023, 63% of abortions were performed with abortion pills — an increase from 2020, when the figure was 53%, according to the Guttmacher Institute. 
  • AstraZeneca to expand cancer pipeline with $2.4B acquisition

    Pharmaceutical company AstraZeneca plans to acquire biotech company Fusion Pharmaceuticals for up to $2.4 billion, Investopedia reported March 19. 
  • 10 common issues in pharmacies

    Unreasonable workload expectations and staffing and scheduling issues ranked highest among negative experiences reported by pharmacy workers in 2023, according to a workplace and well-being report published March 18. 
  • 1st gene therapy for neuron disease in children approved

    On March 18, the FDA approved the first gene therapy for children with metachromatic leukodystrophy, a debilitating, rare genetic disease. 
  • Trinity pharmacy to temporarily close

    Livonia, Mich.-based Trinity Health is temporarily shuttering its pharmacy on Eastern Michigan University's campus. 
  • FDA panel recommends 2 new CAR-T therapies

    After the FDA questioned the safety of two CAR-T therapies, members of the agency's Oncologic Drugs Advisory Committee voted unanimously to recommend Carvykti, made by Janssen Biotech, and voted 8-3 in favor for Abecma, from Bristol-Myers Squibb K.K.
  • Henry Ford Health plans to save $30M with centralized pharmacy

    Detroit-based Henry Ford Health said its centralized pharmacy services center, which opened in September, is designed to save the system $30 million over five years. 
  • FDA approves 1st MASH therapy

    On March 14, the FDA approved the nation's first medication to treat noncirrhotic non-alcoholic steatohepatitis with fibrosis, or fatty liver scarring. 
  • How Mark Cuban's drug company nabbed its 1st health system partnership

    After months of 10 p.m. Saturday emails about utilization trends and "pain points" at Community Health Systems, Mark Cuban Cost Plus Drug Co. secured its first hospital system partnership. Compared to other drugmakers, CHS leaders called the relationship unique. 
  • Pharmacy residency spots are in hot demand: ASHP

    Since 2020, there has been a 10% growth in pharmacy residency positions in the U.S., the American Society of Health-System Pharmacists said March 13. 
  • Man's brain tumor shrinks 60% after 2 months of CAR-T therapy: Study

    In the first study of three recurrent glioblastoma patients treated with CAR T-cell drugs, researchers discovered strong results, with one 72-year-old man's brain tumor shrinking by 60% within two months. 
  • FDA concerns grow over 2 CAR-T therapies

    The FDA has identified increased mortality rates linked to two CAR-T therapies: Carvykti, made by Janssen Biotech, and Abecma, from Bristol-Myers Squibb K.K.
  • Stop dispensing Paxlovid labeled for emergency use, FDA says

    Pharmacies and healthcare providers may no longer dispense Paxlovid labeled in accordance with the FDA's emergency use authorization, the agency said March 13.
  • 9 drugs now in shortage

    Drug, supply and equipment shortages are the eighth-most urgent patient safety concern, the ECRI said March 11. 

Featured Whitepapers

Featured Webinars